The treatment landscape for atopic dermatitis has undergone a transformation in the last seven years, spurred largely by the launch of Sanofi and Regeneron’s blockbuster IL-4/IL-13 inhibitor Dupixent (dupilumab) in 2017. Today, there are a range of topical, oral and biologic drugs and different mechanisms of action available to treat moderate-to-severe atopic dermatitis, but many patients continue to experience persistent itching and remain uncontrolled.
Atopic Dermatitis: A Crowded Field With Room To Grow
Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.
More from Market Intelligence
More from In Vivo
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.